Talia S. Schwartz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Talia S. Schwartz has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alan H. Beggs
Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
4 shared publications - Pankaj B. Agrawal
Division of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children’s Hospital, Jackson Health System, Miami, USA
4 shared publications - Ingrid A. Holm
Department of Pediatrics, Harvard Medical School , Boston, MA 02115
3 shared publications - Monica Hsiung Wojcik
Center for Mendelian Genomics, Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Divisions of Newborn Medicine and of Genetics and Genomics, Boston Children’s Hospital, Harvard Medical School, B
3 shared publications - Amy L. McGuire
Baylor College of Medicine
2 shared publications - Casie A. Genetti
Division of Genetics and Genomics, The Manton Center for Orphan Disease Research, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- Open Access
- 7 February 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 80 (5) , 920-925
Pediatric endoscopic ultrasound‐guided liver biopsy: 3‐year experience
Objectives: Liver biopsy is the gold standard for diagnosing and staging liver diseases. Endoscopic ultrasound‐guided liver biopsy (EUS‐LB) has been reported in adults with equivalent or better safety profiles than percutaneous liver biopsies. The aim of this study was to retrospectively assess the safety and efficacy of EUS‐LB in pediatric patients.Methods: This was a retrospective chart review of consecutive pediatric patients undergoing EUS‐LB at Cincinnati Children's Hospital Medical Center from March 2020 to April 2023. Patients ≤21 years old were included. EUS‐LB was performed via fine‐needle biopsy technique with transduodenal and/or transgastric approach. Histology was independently reviewed by one of two expert pathologists, including length (cm) and complete portal tract (CPT) number per the American Association for the Study of Liver Diseases (AASLD) adequacy criteria. Demographics, clinical data, technical information, diagnostic success, and adverse events were recorded.Results: Eighty‐three patients were included in the analysis, with various indications that required liver biopsy. All biopsies achieved diagnostic and technical success, with 77 (93%) meeting both AASLD criteria for adequacy. Most patients (57, 69%) underwent biopsy of both hepatic lobes, with an overall median of two needle passes. Total specimen length was a median of 7.9 cm (interquartile range [IQR] 5.2–10.3), and the median maximum intact specimen was 4.2 cm (IQR 3.1–5.4). The median CPT number was 24 (IQR 17–32) per patient. Four mild adverse events (5%) occurred; none involved bleeding.Conclusions: EUS‐LB was well tolerated and yielded samples that were technically and diagnostically successful in a pediatric population, with comparable safety to percutaneous liver biopsy.
- 7 February 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 80 (5) , 920-925
Open AccessPediatric endoscopic ultrasound‐guided liver biopsy: 3‐year experience
Objectives: Liver biopsy is the gold standard for diagnosing and staging liver diseases. Endoscopic ultrasound‐guided liver biopsy (EUS‐LB) has been reported in adults with equivalent or better safety profiles than percutaneous liver biopsies. The aim of this study was to retrospectively assess the safety and efficacy of EUS‐LB in pediatric patients.Methods: This was a retrospective chart review of consecutive pediatric patients undergoing EUS‐LB at Cincinnati Children's Hospital Medical Center from March 2020 to April 2023. Patients ≤21 years old were included. EUS‐LB was performed via fine‐needle biopsy technique with transduodenal and/or transgastric approach. Histology was independently reviewed by one of two expert pathologists, including length (cm) and complete portal tract (CPT) number per the American Association for the Study of Liver Diseases (AASLD) adequacy criteria. Demographics, clinical data, technical information, diagnostic success, and adverse events were recorded.Results: Eighty‐three patients were included in the analysis, with various indications that required liver biopsy. All biopsies achieved diagnostic and technical success, with 77 (93%) meeting both AASLD criteria for adequacy. Most patients (57, 69%) underwent biopsy of both hepatic lobes, with an overall median of two needle passes. Total specimen length was a median of 7.9 cm (interquartile range [IQR] 5.2–10.3), and the median maximum intact specimen was 4.2 cm (IQR 3.1–5.4). The median CPT number was 24 (IQR 17–32) per patient. Four mild adverse events (5%) occurred; none involved bleeding.Conclusions: EUS‐LB was well tolerated and yielded samples that were technically and diagnostically successful in a pediatric population, with comparable safety to percutaneous liver biopsy.
- Open Access
- 21 March 2022
- Published by Springer Nature in Research Square
Medical Evaluation of Unanticipated Monogenic Disease Risks Identified through Newborn Genomic Screening: Findings from the BabySeq Project
Genomic sequencing of healthy newborns to screen for medically important genetic information has long been anticipated but data around downstream medical consequences are lacking. Among 159 infants randomized to the sequencing arm in the BabySeq Project, an unanticipated monogenic disease risk (uMDR) was discovered in 18 (11.3%). We assessed uMDR actionability by visualizing scores from a modified ClinGen Actionability SemiQuantitative Metric and tracked medical outcomes in these infants for 3-5 years. All uMDRs scored as highly actionable (mean 9, range: 7-11 on a 0-12 scale) and had readily available clinical interventions. In 4 cases, uMDRs revealed unsuspected genetic etiologies for existing phenotypes, and in the remaining 14 cases provided risk stratification for future surveillance. In 8 cases, uMDRs prompted screening for multiple at-risk family members. These results suggest that actionable uMDRs are more common than previously thought and support ongoing efforts to evaluate population-based newborn genomic screening.
- 21 March 2022
- Published by Springer Nature in Research Square
Open AccessMedical Evaluation of Unanticipated Monogenic Disease Risks Identified through Newborn Genomic Screening: Findings from the BabySeq Project
Genomic sequencing of healthy newborns to screen for medically important genetic information has long been anticipated but data around downstream medical consequences are lacking. Among 159 infants randomized to the sequencing arm in the BabySeq Project, an unanticipated monogenic disease risk (uMDR) was discovered in 18 (11.3%). We assessed uMDR actionability by visualizing scores from a modified ClinGen Actionability SemiQuantitative Metric and tracked medical outcomes in these infants for 3-5 years. All uMDRs scored as highly actionable (mean 9, range: 7-11 on a 0-12 scale) and had readily available clinical interventions. In 4 cases, uMDRs revealed unsuspected genetic etiologies for existing phenotypes, and in the remaining 14 cases provided risk stratification for future surveillance. In 8 cases, uMDRs prompted screening for multiple at-risk family members. These results suggest that actionable uMDRs are more common than previously thought and support ongoing efforts to evaluate population-based newborn genomic screening.
- 26 July 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 31 (1) , 218-229
Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression
Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents’ depressive symptoms were associated with their child's participation in a randomized‐controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post‐disclosure, and 3 months post‐disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow‐up conversations were coded for themes. Forty‐five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post‐disclosure and another 1.1 points 3 months post‐disclosure (both p ≤ .014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post‐disclosure, and decreased by 3.8 points at 3 months post‐disclosure (both p < .001). Nine parents scored above thresholds only at 3 months post‐disclosure after increasing an average of 5.7 points from immediately post‐disclosure (p < .001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.
- 26 July 2021
- Published by Wiley in Journal of Genetic Counseling
- Vol. 31 (1) , 218-229
Effects of participation in a U.S. trial of newborn genomic sequencing on parents at risk for depression
Much emphasis has been placed on participant's psychological safety within genomic research studies; however, few studies have addressed parental psychological health effects associated with their child's participation in genomic studies, particularly when parents meet the threshold for clinical concern for depression. We aimed to determine if parents’ depressive symptoms were associated with their child's participation in a randomized‐controlled trial of newborn exome sequencing. Parents completed the Edinburgh Postnatal Depression Scale (EPDS) at baseline, immediately post‐disclosure, and 3 months post‐disclosure. Mothers and fathers scoring at or above thresholds for clinical concern on the EPDS, 12 and 10, respectively, indicating possible Major Depressive Disorder with Peripartum Onset, were contacted by study staff for mental health screening. Parental concerns identified in follow‐up conversations were coded for themes. Forty‐five parents had EPDS scores above the clinical threshold at baseline, which decreased by an average of 2.9 points immediately post‐disclosure and another 1.1 points 3 months post‐disclosure (both p ≤ .014). For 28 parents, EPDS scores were below the threshold for clinical concern at baseline, increased by an average of 4.7 points into the elevated range immediately post‐disclosure, and decreased by 3.8 points at 3 months post‐disclosure (both p < .001). Nine parents scored above thresholds only at 3 months post‐disclosure after increasing an average of 5.7 points from immediately post‐disclosure (p < .001). Of the 82 parents who scored above the threshold at any time point, 43 (52.4%) were reached and 30 (69.7%) of these 43 parents attributed their elevated scores to parenting stress, balancing work and family responsibilities, and/or child health concerns. Only three parents (7.0%) raised concerns about their participation in the trial, particularly their randomization to the control arm. Elevated scores on the EPDS were typically transient and parents attributed their symptomatology to life stressors in the postpartum period rather than participation in a trial of newborn exome sequencing.
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S93
Optimizing the genetic diagnostic evaluation for critically ill infants
- 1 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S93
Optimizing the genetic diagnostic evaluation for critically ill infants
- 1 February 2019
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 62 (2) , 137-143
Expanding the phenotypic spectrum associated with OPHN1 variants
- 1 February 2019
- Published by Elsevier in European Journal of Medical Genetics
- Vol. 62 (2) , 137-143
Expanding the phenotypic spectrum associated with OPHN1 variants
- Open Access
- 9 July 2018
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 1-10
The BabySeq project: implementing genomic sequencing in newborns
The greatest opportunity for lifelong impact of genomic sequencing is during the newborn period. The “BabySeq Project” is a randomized trial that explores the medical, behavioral, and economic impacts of integrating genomic sequencing into the care of healthy and sick newborns. Families of newborns are enrolled from Boston Children’s Hospital and Brigham and Women’s Hospital nurseries, and half are randomized to receive genomic sequencing and a report that includes monogenic disease variants, recessive carrier variants for childhood onset or actionable disorders, and pharmacogenomic variants. All families participate in a disclosure session, which includes the return of results for those in the sequencing arm. Outcomes are collected through review of medical records and surveys of parents and health care providers and include the rationale for choice of genes and variants to report; what genomic data adds to the medical management of sick and healthy babies; and the medical, behavioral, and economic impacts of integrating genomic sequencing into the care of healthy and sick newborns. The BabySeq Project will provide empirical data about the risks, benefits and costs of newborn genomic sequencing and will inform policy decisions related to universal genomic screening of newborns. The study is registered in ClinicalTrials.gov Identifier: NCT02422511 . Registration date: 10 April 2015.
- 9 July 2018
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 1-10
Open AccessThe BabySeq project: implementing genomic sequencing in newborns
The greatest opportunity for lifelong impact of genomic sequencing is during the newborn period. The “BabySeq Project” is a randomized trial that explores the medical, behavioral, and economic impacts of integrating genomic sequencing into the care of healthy and sick newborns. Families of newborns are enrolled from Boston Children’s Hospital and Brigham and Women’s Hospital nurseries, and half are randomized to receive genomic sequencing and a report that includes monogenic disease variants, recessive carrier variants for childhood onset or actionable disorders, and pharmacogenomic variants. All families participate in a disclosure session, which includes the return of results for those in the sequencing arm. Outcomes are collected through review of medical records and surveys of parents and health care providers and include the rationale for choice of genes and variants to report; what genomic data adds to the medical management of sick and healthy babies; and the medical, behavioral, and economic impacts of integrating genomic sequencing into the care of healthy and sick newborns. The BabySeq Project will provide empirical data about the risks, benefits and costs of newborn genomic sequencing and will inform policy decisions related to universal genomic screening of newborns. The study is registered in ClinicalTrials.gov Identifier: NCT02422511 . Registration date: 10 April 2015.
- 12 April 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 20 (11) , 1396-1404
Genetic disorders and mortality in infancy and early childhood: delayed diagnoses and missed opportunities
- 12 April 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 20 (11) , 1396-1404
Genetic disorders and mortality in infancy and early childhood: delayed diagnoses and missed opportunities